title: Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines.
abstract: Five-year survival rate for lung cancer is limited to 10% to 15%. Therefore, the identification of novel therapeutic prognostic factors is an urgent requirement. The aim of this study is thus to highlight specific biomarkers in chemoresistant non-small cell lung cancer cell lines. Therefore, we checked-in the control condition as well as after short-term pharmacological treatment with either docetaxel or gemcitabine-the expression of genes such as tumor suppressor genes (CDKN2A, DAPK, FHIT, GSTP1, MGMT, RARβ2, RASSF1A, and TIMP3), genes associated with drug resistance (BRCA1, COX2, ERCC1, IGFBP3, RRM1, and TUBB3), and stemness-related genes (CD133, OCT4, and SLUG) in two cellular models of squamous carcinoma (CAEP) and adenocarcinoma (RAL) of the lung originally established. Their promoter methylation profile was also evaluated. Drug-related genes were upregulated. Cisplatin resistance matched with high levels of BRCA1 and ERCC1 in both cell lines; docetaxel sensitivity of CAEP cells was associated to levels of TUBB3 lower than RAL cells. Although CAEP cells were more sensitive to gemcitabine, both cell lines showed high levels of RRM1. Stemness-related genes were downregulated in the control condition but became upregulated in docetaxel-resistant cells, indicating the selection of a population with stemness features. We did not find an unequivocal correspondence between gene expression and respective DNA promoter methylation status, suggesting the involvement of additional mechanisms of gene expression regulation. These results highlight specific biomarkers consistent with the different responses of the two cell lines to standard pharmacological treatments and indicate specific molecular traits for their chemoresistance.
authors: Laboratory of Cellular and Molecular Engineering "S. Cavalcanti", School of Engineering, University of Bologna, Campus of Cesena, Cesena, Italy.
authors: Alice
authors: A
authors: Pasini
authors: Giulia
authors: G
authors: Paganelli
authors: Anna
authors: A
authors: Tesei
authors: Wainer
authors: W
authors: Zoli
authors: Emanuele
authors: E
authors: Giordano
authors: Daniele
authors: D
authors: Calistri
references: Cancer Metastasis Rev. 2010 Mar;29(1):95-107
references: 20099008
references: Clin Cancer Res. 2004 Mar 15;10(6):1976-83
references: 15041715
references: Cancer Res. 2004 Jun 1;64(11):3761-6
references: 15172981
references: Dev Cell. 2010 Nov 16;19(5):698-711
references: 21074720
references: PLoS One. 2008 Aug 27;3(8):e3077
references: 18728788
references: PLoS One. 2008 Jul 09;3(7):e2637
references: 18612434
references: Lung Cancer. 2012 Mar;75(3):374-80
references: 21889227
references: Dis Markers. 2007;23(1-2):5-30
references: 17325423
references: Lung Cancer. 2010 Jun;68(3):478-83
references: 19683826
references: Semin Surg Oncol. 2000 Mar;18(2):91-9
references: 10657910
references: Crit Rev Oncol Hematol. 2010 Sep;75(3):173-234
references: 20047843
references: Cell Prolif. 2009 Jun;42(3):298-308
references: 19438897
references: Cancer Lett. 2011 Feb 1;301(1):7-16
references: 21087818
references: Pharmacol Rev. 2003 Mar;55(1):57-103
references: 12615954
references: Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6
references: 19805294
references: Int J Cancer. 2006 Apr 1;118(7):1692-8
references: 16231322
references: Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6
references: 8790415
references: Crit Rev Oncol Hematol. 2007 Jul;63(1):12-31
references: 17336087
references: J Transl Med. 2011 Jun 20;9:94
references: 21689426
references: Nat Biotechnol. 2010 Oct;28(10):1057-68
references: 20944598
references: Curr Genomics. 2009 Aug;10(5):336-52
references: 20119531
references: Br J Cancer. 2004 Aug 16;91(4):771-4
references: 15266335
references: J Natl Cancer Inst. 2000 Aug 16;92(16):1303-7
references: 10944551
references: Lung Cancer. 2001 Dec;34 Suppl 2:S27-34
references: 11720738
references: Curr Opin Genet Dev. 2011 Apr;21(2):140-6
references: 21316216
references: BMC Cancer. 2008 Apr 11;8:97
references: 18402708
references: J Natl Cancer Inst. 2001 May 2;93(9):691-9
references: 11333291
references: Development. 2009 Nov;136(21):3531-42
references: 19820181
references: Int J Cancer. 2010 Feb 15;126(4):950-8
references: 19676044
references: Cancer Res. 2006 Apr 15;66(8):4049-54
references: 16618724
references: PLoS One. 2007 Nov 07;2(11):e1129
references: 17987116
references: J Clin Oncol. 2008 Jun 10;26(17):2883-9
references: 18539968
references: Cell Death Differ. 2008 Mar;15(3):504-14
references: 18049477
references: J Cell Physiol. 2007 Sep;212(3):710-6
references: 17458894
references: J Clin Oncol. 2000 Jun;18(12):2354-62
references: 10856094
references: J Clin Oncol. 2000 May;18(10):2095-103
references: 10811675
references: Target Oncol. 2010 Mar;5(1):5-17
references: 20443070
references: Br J Cancer. 2000 Mar;82(6):1191-7
references: 10735505
references: Lung Cancer. 2004 Dec;46(3):305-12
references: 15541815
references: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references: 15761078
references: J Transl Med. 2010 Sep 17;8:86
references: 20849603
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Br J Cancer. 1999 Oct;81(4):609-15
references: 10574245
references: Cancer Genet Cytogenet. 1998 Nov;107(1):11-20
references: 9809028
references: J Cell Physiol. 2012 Oct;227(10):3389-96
references: 22212895
references: Nat Rev Cancer. 2004 Sep;4(9):707-17
references: 15343277
references: Oncologist. 2002;7(5):451-7
references: 12401908
references: Int J Cancer. 2003 Aug 10;106(1):45-51
references: 12794755
references: Crit Rev Oncol Hematol. 2010 Aug;75(2):94-109
references: 19914087
references: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references: 2359136
references: Cancer Metastasis Rev. 2010 Mar;29(1):61-72
references: 20094757
references: Am J Health Syst Pharm. 2010 Jan 1;67(1 Suppl 1):S3-9, quiz S15-6
references: 20044377
references: Clin Cancer Res. 2005 Feb 15;11(4):1669-74
references: 15746072
references: Surg Today. 2010 Jul;40(7):602-7
references: 20582509
references: Lung Cancer. 2008 Mar;59(3):377-84
references: 17905465
references: Adv Drug Deliv Rev. 2009 May 20;61(5):408-17
references: 19292993
references: Eur J Cancer. 2005 May;41(8):1223-36
references: 15911247
references: Lung Cancer. 2003 Jan;39(1):71-6
references: 12499097
references: Dis Markers. 2008;24(4-5):257-66
references: 18525120
references: Crit Rev Oncol Hematol. 2005 Jul;55(1):1-11
references: 15886007
references: Prog Exp Tumor Res. 2003;37:138-62
references: 12795053
references: Oncogene. 2010 Mar 18;29(11):1681-90
references: 20023704
references: Pulm Pharmacol Ther. 2010 Dec;23(6):508-14
references: 20471486
references: Oncogene. 2002 Aug 12;21(35):5450-61
references: 12154407
references: Nat Biotechnol. 2009 Jan;27(1):44-6
references: 19131997
references: Clin Cancer Res. 2003 Feb;9(2):703-10
references: 12576438